Lys319
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys319  -  PSF (human)

Site Information
EFkRLFAkyGEPGEV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 474896
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:
colorectal cancer ( 7 ) , colorectal carcinoma ( 7 ) , leukemia ( 5 , 6 ) , chronic myelogenous leukemia ( 5 , 6 ) , lung cancer ( 1 , 2 ) , non-small cell lung adenocarcinoma ( 1 ) , small-cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 1 ) , DMS79 (pulmonary) ( 2 ) , HCT116 (intestinal) ( 7 ) , Jurkat (T lymphocyte) ( 3 , 8 , 9 , 10 ) , K562 (erythroid) ( 5 , 6 ) , lung ( 2 ) , NCI-H128 (pulmonary) ( 2 ) , NCI-H1417 (pulmonary) ( 2 ) , NCI-H209 (pulmonary) ( 2 ) , NCI-H524 (pulmonary) ( 2 )

Upstream Regulation
Treatments:
vorinostat ( 1 )

References 

1

Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520
25825284   Curated Info

2

Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

4

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

5

Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Moritz A (2010) CST Curation Set: 9817; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

7

Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

8

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

9

Possemato A (2006) CST Curation Set: 2193; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

10

Possemato A (2006) CST Curation Set: 2194; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info